Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLO-329 · 1 trial · 3 indications
The incidence of dose limiting toxicities (DLTs) and other safety parameters (including but not limited to treatment emergent adverse events \[AEs\], serious adverse events \[SAEs\], and clinical laboratory abnormalities)
| Arm | Type | Description |
|---|---|---|
| ALLO-329, Cyclophosphamide | EXPERIMENTAL | Participants receive ALLO-329 following lymphodepletion regimen comprised of cyclophosphamide. |
| ALLO-329 | EXPERIMENTAL | Participants receive ALLO-329 without a lymphodepletion regimen. |
| ALLO-329, Cyclophosphamide, Fludarabine | EXPERIMENTAL | Participants receive ALLO-329 following lymphodepletion regimen comprised of cyclophosphamide and fludarabine. |
| Name | Type | Description |
|---|---|---|
| ALLO-329 | GENETIC | An allogeneic CAR T cell therapy targeting CD19 and CD70 |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: 1. Adults ≥ 18 to \< 70 years of age. 2. Adequate hematological function and liver, cardiac, and pulmonary function. 3. A highly sensitive urine pregnancy test or serum pregnancy test (for females of childbearing potential) negative at screening. All participants of childbearing...